TGFB1 and neoplasm: At the same time, SPARC can also bind to platelet-derived growth factor PDGF to indirectly inhibit angiogenesis by downregulating matrix metalloproteinases (MMPs) and transforming growth factor β1 antibodies (TGF-β1), which in turn inhibits tumor invasion and metastasis [9, 10].